CJ CheilJedang steps up biotech drive with PHA mass production Korean food and bio company begins mass production of biodegradable plastic
Translated by Ryu Ho-joung 공개 2022-05-16 08:05:48
이 기사는 2022년 05월 13일 08:00 thebell 에 표출된 기사입니다.
South Korea’s CJ CheilJedang started mass production of polyhydroxyalkanoate (PHA) biodegradable plastic at its plant in Pasuruan, Indonesia, the company said on Wednesday, a move in line with its drive to expand its biotech business for future growth.The plant can produce 5,000 metric tons of amorphous PHA a year. PHA is a natural polyester polymer that can be totally decomposed in the ocean and soil and thus is a viable alternative to petroleum-based plastic.
CJ CheilJedang has proprietary amorphous PHA technology, which is used as a modifier to other polymers to improve processing characteristics. It is the only company in the world that succeeded in mass-producing amorphous PHA.
CJ CheilJedang is also building a facility that will produce semi-crystalline PHA, which are used to make things like medical supplies, fibers and straws. The company plans to increase its PHA production capacity to 65,000 metric tons a year by 2025.
“Our ability to produce both amorphous PHA and semi-crystalline PHA gives us an edge over competitors in expanding the business,” an official at CJ CheilJedang said. Other PHA producers like US-based Danimer Scientific and Japan’s Kaneka Corporation make semi-crystalline PHA only.
CJ CheilJedang secured contracts to supply over 5,000 metric tons of amorphous PHA to global companies even before the mass production began.
The global biodegradable plastic market is expected to grow to 16 trillion won ($12.5 billion) in 2025 from about 5 trillion won last year amid tightened environmental rules, especially in developed countries, that are accelerating a shift to environmentally friendly packaging.
Biopharmaceutical ambitions
In July last year, CJ CheilJedang acquired bioinformatics company ChunLab, now renamed CJ Bioscience, for about 100 billion won in a deal to expand its business to include biopharmaceutical products.
CJ Bioscience is still in the red and is expected to take time to turn profitable. CJ CheilJedang recorded 60.9 billion won in goodwill related to CJ Bioscience at the end of 2021, suggesting it believes in the biopharmaceutical company’s growth potential.
CJ CheilJedang also purchased a 76% stake in Batavia Biosciences, a Dutch biotechnology contract manufacturer, for 267.7 billion won in November last year.
“We will continue to make efforts and investment in R&D to strengthen the competitiveness of our biotech business and improve profitability,” the CJ CheilJedang official said. (Reporting by Nu-ri Moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감